trending Market Intelligence /marketintelligence/en/news-insights/trending/zU150WP5O9FPgAqLyl2sAA2 content esgSubNav
In This List

Dynavax plans common stock offering

Case Study

Identifying PPE Suppliers During the Pandemic


Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage


COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021


Corporate Credit Risk Trends in Developing Markets: A Loss Given Default (LGD) Perspective

Dynavax plans common stock offering

Dynavax Technologies Corp. plans to sell $125.0 million of its common stock, subject to market and other conditions, in an underwritten public offering.

The company will also grant underwriters an overallotment option to buy up to an additional $18.8 million of common stock.

Dynavax plans to use the net proceeds to fund activities associated with preparing for the anticipated U.S. commercial launch of HEPLISAV-B after the drug gains approval by the U.S. Food and Drug Administration.

In addition, the net proceeds will support continuing the clinical development of its lead investigational cancer immunotherapeutic product candidates, SD-101 and DV281, continuing research and development activities and for other general corporate purposes, including working capital.

Cowen, RBC Capital Markets and William Blair are acting as joint book-running managers for the offering. Cantor Fitzgerald & Co. is acting as lead manager for the offering.